Aura Biosciences, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone 2023 Q4 report; quarterly financial results are not separately summarized in the provided filing text.
Business context
Aura is a clinical-stage biotechnology company with no approved products or product-sales revenue. Its lead candidate, bel-sar (AU-011), is a virus-like drug conjugate being developed primarily as a potential vision-sparing treatment for early-stage choroidal melanoma. The company is also studying bel-sar in bladder cancer and pursuing other ocular oncology indications.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $65.2 million | $42.2 million |
| General and administrative expense | $19.8 million | $18.1 million |
| Total operating expenses / operating loss | $85.0 million | $60.3 million |
| Net loss | $76.4 million | $58.8 million |
| Net loss per share, basic and diluted | $1.93 | $1.96 |
| Net cash used in operating activities | $63.8 million | $54.6 million |
| Net cash used in investing activities | $114.0 million | $67.9 million |
| Net cash provided by financing activities | $97.3 million | $95.6 million |
- Net loss widened by $17.6 million. R&D expense rose by $23.0 million, mainly due to clinical-trial progression, the start of the global Phase 3 trial, and bel-sar manufacturing and development. G&A expense increased by $1.7 million.
- Interest income, including amortization and accretion, increased to $8.6 million from $1.9 million, partly offsetting operating losses.
- At year-end, cash and cash equivalents were $41.1 million and marketable securities were $185.1 million, totaling approximately $226.2 million. Current assets were $231.8 million and current liabilities $12.4 million.
- Total liabilities were $29.2 million, primarily operating lease liabilities; the company reported no long-term debt. Lease commitments totaled $30.5 million, with the Boston lease running through August 2032.
- In November 2023, Aura raised $99.0 million gross, or approximately $92.6 million net, through a follow-on stock offering. It also raised $3.3 million gross under its ATM program during 2023; the ATM prospectus was suspended after the follow-on offering. Shares outstanding increased to 49.35 million from 37.77 million.
- No meaningful revenue-based margins are available because Aura has not generated product revenue. The filing reports no material legal proceedings as of December 31, 2023. The independent auditor issued an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting, without an auditor attestation.
Clinical progress, outlook, and key risks
- Choroidal melanoma: The ongoing global Phase 3 CoMpass trial compares bel-sar with sham and is designed to enroll approximately 100 patients. Its primary endpoint is time to tumor progression. The FDA agreed to the study design and planned analysis under a Special Protocol Assessment (SPA); the SPA does not guarantee approval. The filing does not report Phase 3 efficacy results.
- Phase 2 interim results: In the suprachoroidal study, patients in the three-cycle cohorts matching Phase 3 criteria had an interim tumor-control rate of 80% (8/10) and visual-acuity preservation rate of 90% (9/10). These are small, interim results, not confirmatory Phase 3 evidence. Final Phase 2 data were expected by the end of 2024.
- Other programs: Aura planned to initiate a Phase 2 study in choroidal metastases in 2024, with initial data expected by year-end 2024. Its Phase 1 bladder-cancer study includes non-muscle-invasive and muscle-invasive disease; early data were expected in mid-2024. A complete response was reported in the first light-activated patient, a preliminary observation requiring confirmation.
- Runway and funding: Management estimated that year-end cash, cash equivalents, and marketable securities would fund operating expenses and capital needs into the second half of 2026, based on its current plan. The filing cautions that the estimate depends on assumptions and that additional capital will be needed to complete development and commercialization. Further financing could dilute shareholders or constrain operations.
- Principal risks: Aura depends heavily on bel-sar, has no commercial revenue, and expects continuing losses. Key uncertainties include Phase 3 success and regulatory requirements, patient enrollment, manufacturing scale-up and reliance on single-source external suppliers, clinical-trial safety, intellectual-property protection, reimbursement and market acceptance, and the availability and terms of future financing. Bel-sar’s drug-device/laser delivery approach adds regulatory and operational complexity.
- Management also cited competitive pressure in bladder cancer, potential pricing and reimbursement constraints, and macroeconomic and capital-market uncertainty. Bel-sar has FDA Fast Track designation for choroidal melanoma, choroidal metastasis, and non-muscle-invasive bladder cancer, and orphan-drug designations for uveal melanoma in the U.S. and EU; these designations do not assure approval.
Important facts for investors to verify
- Current enrollment, trial conduct, and timing for the CoMpass Phase 3 study, and what data and regulatory steps will be required for a BLA.
- Final Phase 2 results and whether they support the interim tumor-control and vision-preservation findings.
- Actual cash burn and updated runway versus management’s second-half-2026 estimate; financing needs and potential dilution.
- Progress on commercial-process transfer, CDMO capacity, supply redundancy, and any need for clinical comparability studies.
- Bladder-cancer and choroidal-metastasis trial progress, including whether expected data milestones occurred and how robust the early findings are.
- Patent and license status, including the expiration of the licensed LI-COR patent in December 2023 and the economics of milestone and royalty obligations.